Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

Development and targeted use of nilotinib in chronic myeloid leukemia

Authors Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Published 10 November 2008 Volume 2008:2 Pages 233—243


Review by Single-blind

Peer reviewer comments 3

Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.

Keywords: nilotinib, imatinib-resistance, imatinib-intolerance, CML

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Core Evidence 2009, 4:207-213

Published Date: 5 October 2009

Readers of this article also read:

Functionalized magnetic iron oxide/alginate core-shell nanoparticles for targeting hyperthermia

Liao SH, Liu CH, Bastakoti BP, Suzuki N, Chang Y, Yamauchi Y, Lin FH, Wu KCW

International Journal of Nanomedicine 2015, 10:3315-3328

Published Date: 4 May 2015

Corneal decompensation following filtering surgery with the Ex-PRESS® mini glaucoma shunt device

Tojo N, Hayashi A, Miyakoshi A

Clinical Ophthalmology 2015, 9:499-502

Published Date: 17 March 2015

Folate-modified lipid–polymer hybrid nanoparticles for targeted paclitaxel delivery

Zhang L, Zhu D, Dong X, Sun H, Song C, Wang C, Kong D

International Journal of Nanomedicine 2015, 10:2101-2114

Published Date: 16 March 2015

In vitro and in vivo effects of graphene oxide and reduced graphene oxide on glioblastoma

Jaworski S, Sawosz E, Kutwin M, Wierzbicki M, Hinzmann M, Grodzik M, Winnicka A, Lipińska L, Włodyga K, Chwalibog A

International Journal of Nanomedicine 2015, 10:1585-1596

Published Date: 25 February 2015

Targeting and treatment of glioblastomas with human mesenchymal stem cells carrying ferrociphenol lipid nanocapsules

Clavreul A, Montagu A, Lainé AL, Tétaud C, Lautram N, Franconi F, Passirani C, Vessières A, Montero-Menei CN, Menei P

International Journal of Nanomedicine 2015, 10:1259-1271

Published Date: 12 February 2015

Effects of immunosuppressive treatment on protein expression in rat kidney

Kędzierska K, Sporniak-Tutak K, Sindrewicz K, Bober J, Domański L, Parafiniuk M, Urasińska E, Ciechanowicz A, Domański M, Smektała T, Masiuk M, Skrzypczak W, Ożgo M, Kabat-Koperska J, Ciechanowski K,

Drug Design, Development and Therapy 2014, 8:1695-1708

Published Date: 30 September 2014

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010